Psychopharmacology
December 18, 2019
Neiloufar Family, Émeline L. Maillet, Luke T. J. Williams et al.
142 citations
Repeated low doses of LSD are safe and well tolerated in older adults. In a double-blind, placebo-controlled trial, 48 healthy volunteers aged around 63 received either 5, 10, or 20 micrograms of LSD or a placebo every four days for three weeks. LSD was undetectable in the blood at the 5 microgram dose, while peak levels for higher doses occurred within 30 minutes. Adverse events were no more frequent than with placebo, and tests of cognition, balance, and proprioception showed no impairment. These results support further clinical development of low-dose LSD for treating or preventing Alzheimer's disease.
Journal of Psychopharmacology
March 1, 2022
Neiloufar Family, Peter S. Hendricks, Luke T. J. Williams et al.
23 citations
LSD doses of 50, 75, and 100 micrograms are tolerable and safe in healthy adults when administered in a novel group-based intervention paradigm with one attendant per participant. Thirty-two adults (mean age 28.8 years) received LSD or placebo across open-label and double-blind designs. No serious adverse events occurred; 28% of participants reported at least one mild expected adverse event and one moderate event. Peak blood plasma levels appeared 1.2 to 2 hours after administration, with an apparent half-life of 2.8 to 4.3 hours. LSD produced greater subjective effects than placebo, including mystical-type experiences. Further research is needed in clinical populations.
Journal of Psychopharmacology
March 1, 2022
Peter S. Hendricks, Heith Copes, Neiloufar Family et al.
8 citations
In a proof-of-concept study with 31 healthy participants given 50 to 100 µg of LSD, most felt safe throughout the experiment, attributing their comfort to the study structure and support from attendants, which allowed them to let go and immerse themselves. A minority initially worried about having a challenging experience, but those concerns lessened over time. Participants reported transcendent, mystical-type experiences typical of classic psychedelics, with nearly half noting the important role of music during the drug's acute effects. They endorsed the clinical utility of LSD in controlled environments, believing it is safe and could help others. Findings suggest this scalable intervention paradigm is feasible and warrants further research with clinical populations.